S
SYNACT
vs
O
OMX Stockholm 30
Over the past 12 months, SYNACT has underperformed OMX Stockholm 30, delivering a return of -6% compared to the OMX Stockholm 30's +33% growth.
Stocks Performance
SYNACT vs OMX Stockholm 30
Performance Gap
SYNACT vs OMX Stockholm 30
Performance By Year
SYNACT vs OMX Stockholm 30
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
SynAct Pharma AB
Glance View
SynAct Pharma AB engages in the development of pharmaceutical drugs for the treatment of inflammatory diseases. The company is headquartered in Lund, Skane. The company went IPO on 2016-07-11. The firm is located in Lund, Sweden. The company develops medicines for acute impairment in inflammatory diseases. The firm's drug candidate AP1189 is intended for the treatment of arthritis including psoriasis arthritis.